Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses findings from abstract S3-02, “NSABP B-36: A randomized phase III trial comparing six cycles of fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients with node-negative breast cancer.”
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:
Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract P5-19-09, “Stage 1 results from MDV3100-11: A two-stage study of enzalutamide, an androgen receptor inhibitor, in advanced androgen receptor–positive triple-negative breast cancer,” presented by Tiffany A. Traina, MD.
Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials:
• B-40, the only study to combine neoadjuvant and adjuvant chemotherapy with bevacizumab
• B-51, on radiation to the chest wall
• Alliance trial, on lymph node dissection
Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract PD2-1, “The effect on overall and disease-free survival by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40.”
Lisa A. Carey, MD, of UNC Lineberger Comprehensive Cancer Center, offers her thoughts on abstract S1-09, "A phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.
